D.E. Shaw & Co
ELVN icon

D.E. Shaw & Co’s Enliven Therapeutics ELVN Stock Holding History

D.E. Shaw & Co’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
305,703
+112,172
+58% +$4.76M 0.01% 1477
2026
Q1 		$7.59M Buy
+193,531
New +$5.36M ﹤0.01% 1845
2022
Q1 		– Sell
-20,967
Closed -$189K – 5630
2021
Q4 		$189K Buy
20,967
+5,469
+35% +$71.7K ﹤0.01% 4900
2021
Q3 		$253K Buy
+15,498
New +$322K ﹤0.01% 4451

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

D.E. Shaw & Co's ELVN Position: Q2 2026 in Review

D.E. Shaw & Co increased its Enliven Therapeutics (ELVN) stake by 58% in Q2 2026, buying an estimated $4.76M and bringing the position to 305,703 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1477.

D.E. Shaw & Co first reported a position in ELVN in Q3 2021 and has held it in 4 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • D.E. Shaw & Co held 305,703 shares of Enliven Therapeutics worth $15.5M as of Q2 2026.
  • D.E. Shaw & Co bought 112,172 Enliven Therapeutics shares in Q2 2026, an estimated $4.76M.
  • Enliven Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1477 holding.
  • D.E. Shaw & Co first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.